ArticleThe Journal of biological chemistry2021
Hepatocyte-specific perturbation of NAD
Article in The Journal of biological chemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 35 citations in OpenAlex.
- Dietary Protein Restriction Improves Metabolic Dysfunction in Patients with Metabolic Syndrome in a Randomized, Controlled Trial.Nutrients · 2022Trial
- Discovery of 5' NAD capped viral RNAs reveals evolutionary divergent 5' metabolite capping across hepaciviruses.Nature communications · 2026Article
- NAMPT improves high-fat diet-induced nonalcoholic fatty liver disease (NAFLD) via the SIRT1-C/EBPβ-STEAP4-NRF2 axis.Journal of molecular cell biology · 2026Article
- Expression of CD38Scientific reports · 2026Article
- NADNature metabolism · 2025Review
- Emerging strategies, applications and challenges of targeting NADNature aging · 2025Review
- Intestinal Fut2 deficiency exacerbated alcohol-related liver disease by disrupting nicotinamide metabolism.Clinical and translational medicine · 2025Article
- Article
- NAD metabolic therapy in metabolic dysfunction-associated steatotic liver disease: Possible roles of gut microbiota.iScience · 2024Review
- Nuclear Nicotinamide Adenine Dinucleotide Deficiency by Nmnat1 Deletion Impaired Hepatic Insulin Signaling, Mitochondrial Function, and Hepatokine Expression in Mice Fed a High-Fat Diet.Laboratory investigation; a journal of technical methods and pathology · 2024Article
- Hepatic steatosis induced by nicotine plus Coca-Cola™ is prevented by nicotinamide riboside (NR).Frontiers in endocrinology · 2024Article
- Nicotinamide Riboside, a Promising Vitamin BMolecules (Basel, Switzerland) · 2023Review
- Interactions between Intestinal Homeostasis and NADNutrients · 2023Review
- Hepatic Nampt Deficiency Aggravates Dyslipidemia and Fatty Liver in High Fat Diet Fed Mice.Cells · 2023Article
- Identification of Cuproptosis-Related Genes in Nonalcoholic Fatty Liver Disease.Oxidative medicine and cellular longevity · 2023Article
- Adipokines in Non-Alcoholic Fatty Liver Disease: Are We on the Road toward New Biomarkers and Therapeutic Targets?Biology · 2022Review
- Balancing NADCellular and molecular life sciences : CMLS · 2022Review
- NADMetabolites · 2022Review
- Review
- Integrated Liver and Plasma Proteomics in Obese Mice Reveals Complex Metabolic Regulation.Molecular & cellular proteomics : MCP · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 1 institution in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nicotinamide phosphoribosyltransferase (NAMPT) converts nicotinamide to NAD
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.